Acute myeloid leukemia (AML) with chromosomal rearrangements inv(16)(p13q22) or t(16;16)(p13;q22) (collectively referred to as inv (16)) and t(8;21)(q22;q22) are classified as core binding factor (CBF) AML, which accounts for~20% of all AML cases. 1 The resulting oncogenic fusion genes, CBFB-MYH11 and RUNX1-RUNX1T1, respectively, involve members of the CBF family of transcription factors, RUNX1 and its binding partner CBFβ.
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Thus, it is imperative to develop novel and 'personalized' treatments for these patients. However, the mechanisms leading to relapse remain elusive. The goal of our study was to elucidate the mechanisms of relapse in CBF AML by unbiased genomic approaches. Therefore, we applied whole-exome sequencing (WES) and single-nucleotide polymorphism (SNP) arrays to analyze the somatic mutational landscape of matched diagnosis and relapse DNA samples from CBF AML patients. Here we report our data on the identification of putative novel AML driver genes and mechanisms of relapse.
WES and SNP arrays were performed on diagnosis, CR and relapse samples from 10 patients and diagnosis and relapse samples from additional three patients on the CALGB 8461 protocol. 4 Patient details and study design are described in Supplementary methods, Supplementary Table S1 and Supplementary Figure S1 . DNA from CR samples was used as the germline control to identify somatic single-nucleotide variants (SNVs) and copy-number variants (CNVs). We obtained high quality WES reads with average breadth of coverage of 90.5% of exome (range: 85-93%) and average depth of coverage of 82.4 × (range: 39.3-108.4 × ; Supplementary Table S2) .
To identify genes involved in CBF AML, we focused on the variants with nonsynonymous amino acid changes, splicing changes, and coding region indels (collectively referred to as SNVs). Furthermore, breakpoint analysis identified FLT3-ITD (internal tandem duplications of 35-84 bp) in three patients. A total of 174 unique variants in 163 genes met the criteria of being 'somatic' based on their absence in the corresponding germline DNA sample, ruled out as a sequencing artifact and variant allele frequency (VAF) of ⩾ 0.10 with high-quality reads (Supplementary Tables S3 and S4 ). For the patients lacking WES data on the CR sample, we identified somatic SNVs by manual validation of variants in known AML genes (Supplementary  Tables S5 and S6 ). More than half of the somatic variants were predicted to have deleterious effects on the functions of the corresponding proteins (Figure 1a) . However, we did not find any specific pathways to be significantly enriched among the mutated genes. To understand the relationship between diagnosis and relapse samples, we classified the variants for each patient into those shared by the matched diagnosis and relapse samples and those specific to either time-point (Figure 1b and Supplementary  Table S4 ). Consistent with the previous studies in AML, 5 the total number of somatic variants per sample ranged from 5 to 18 (Figure 1b) . Relapse samples gained one to eleven additional somatic variants compared with the corresponding diagnosis samples. Two distinct patterns of tumor evolution were evident: (1) diagnosis and relapse leukemias share the majority of the somatic variants indicating origin from a common clone (for example, AET4 and INVT3); (2) relapse leukemias lost some of the variants detected in the corresponding diagnostic samples, indicating origin from an ancestral preleukemic clone (for example, AET2, INVT2, INVT4 and INVT5).
We identified somatic variants in at least one of ten previously known AML driver genes (FLT3, KIT, NRAS, WT1, SMC1A, SMC3, DNMT3A, EZH2, SPI1 and RAD21, (refs 5,6 ) in all patients except INVT2 ( Figure 1c and Supplementary Tables S3 and S4 ). FLT3 and KIT were the top two recurrently mutated genes in our patient cohort (Figure 1c , Supplementary Table S7 ). FLT3-ITD was detected in diagnosis and relapse samples in five patients, whereas a relapse-specific F594I mutation (in the juxtamembrane domain) was detected in one patient (Supplementary Table S7 ). KIT mutations in both exons 8 (residues 417-421) and 17 (D816) were detected (Supplementary Table S7 ). Interestingly, the diagnosis sample in patient AET3 showed two KIT variants, D816Y and N822K (VAF = 0.27 and 0.13 respectively), while the relapse sample contained D816Y variant only (VAF = 0.54; Figure 1c , Supplementary Table S7 ), indicating at least two clones during diagnosis of which the dominant clone with D816Y is resistant to therapy, leading to relapse.
From the remaining 153 genes (75 shared, 24 diagnosis specific and 54 relapse specific), DHX15 was the only gene mutated in more than one patient. We detected an identical nonsynonymous variant causing R222G (genomic coordinates: chr 4: G24572314C) in patients AET1 and AET3. Interestingly, the variant was lost in corresponding relapse sample from patient AET1 (Supplementary  Figure S2, Supplementary Tables S3 and S4 ), indicating origin of relapse leukemia from an ancestral clone. The variant is predicted to be damaging by SIFT and is not detected in 938 controls from the Clinseq project. 7 The affected amino-acid R222 is part of the DEXDc domain, and is evolutionarily conserved from mammals to yeast ( Figure 1d ). Our data, combined with the previous report of the same variant in a patient with refractory anemia with excess blasts, a form of myelodysplastic syndrome with predisposition to AML, 8 suggest DHX15 as a potential new AML driver gene. Functional analyses of Prp43, the yeast homolog of DHX15, have demonstrated its role in the release of the intron lariat during RNA splicing, 9 thus adding DHX15 to the growing list of splicing factors involved in AML. 5 Next we analyzed the SNP array data from 4900 000 polymorphic markers to identify recurrently occurring CNVs with putative roles in the relapse of CBF AML. We identified 52 somatic CNVs ranging in size from 20 kb to an entire chromosome (Supplementary Table S8 ). Consistent with the previous data, compared with the diagnosis samples (Figure 1e , Supplementary  Table S8 ). In particular, relapsed leukemia cells from patient AET3 harbored 17 somatic CNVs compared with only one CNV in its diagnosis sample (Supplementary Table S8 ). Importantly, even after removing AET3 the rest of the relapse samples still showed increased CNVs (Supplementary Figure S3) . Of the 11 genomic regions with recurrent CNVs (Figure 1f, Supplementary Figure S4) , trisomy 8 is known to be involved in AML and has been detected in 16% of AML patients with inv (16) . 12 Among the CNVs affecting subchromosomal regions, deletion of overlapping regions on chromosome 3 was detected in relapse samples from three patients (Figure 1g, Supplementary Figure S4) . The minimal 
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D.melanogaster # of somatic variants AET3  AET4  AET2  AET7  AET5  INVT2 INVT7 INVT5  INVT3 INVT4 # of variants unique to tumor at relapse # of variants unique to tumor at diagnosis # of variants shared between diagnosis and relapse overlapping region of deletions in these relapse samples (chr3: 127965570-128209667) contains EEFSEC, DNAJB8 and GATA2. Of these, GATA2 encodes a master regulator of hematopoiesis. Recent studies have shown that both mutations and expression level changes in GATA2 play a causative role in AML. [13] [14] [15] Our observation is the first indication that GATA2 haploinsufficiency may be important for CBF leukemia relapse.
We deduced clonal evolution during relapse by integrated analysis of the SNVs and CNVs in matched diagnosis and relapse samples ( Figure 2 ). Our data suggested two potential mechanisms of relapse: (1) a subclone of the diagnosis leukemia survived therapy and reemerged after accumulating additional mutations; (2) a preleukemia clone survived therapy, acquired additional mutations during remission, and gave rise to relapse leukemia ( Figure 2 ). Common to both mechanisms is the existence of a clone with potential to evolve into leukemia that was not completely eliminated by the treatment after diagnosis. These findings are consistent with other recent studies involving analysis of matched diagnosis and relapse AML samples. 11, 16, 17 It is worth noting that the RUNX1-RUNX1T1 and CBFB-MYH11 fusion genes were present at both diagnosis and relapse in all patients and mutations in one or more of the known AML driver genes tend to be present at both stages as well. On the other hand, mutations that emerged at relapse are mostly in the genes that have not been previously linked to leukemia. Additional CBF AML samples need to be screened for mutations in these genes and functional studies need to be carried out to determine if they contribute to relapse.
In summary, we have systematically surveyed the genomic landscape of CBF AML at both diagnosis and relapse, and deduced two potential mechanisms of relapse. This study can serve as a starting point for future investigations into the mechanism of CBF AML relapse. Genes and chromosomal regions identified here, specifically DHX15 and GATA2, can be screened by targeted approaches in additional CBF AML patients to determine their contribution to CBF AML and its relapse. Combining our data with findings from previous studies on the clonal evolution of relapse leukemias suggest that targeting the leukemia initiating events, such as the CBF fusion proteins and mutations in known driver genes should be explored further to lower the incidence of relapse. 
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